Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical United States Government Payers

Aetna’s Generic Gleevec Approach Combines Specialty Tiering, ‘Fail First’ Strategy

  • News

Executive Summary

Aetna oncology exec Kolodziej says the insurer expects the price discount for generic imatinib compared to the brand will be relatively modest at first.

You may also be interested in...



CVS Expands Formulary Exclusions In 2017, Express Scripts’ Tally Unchanged

National formulary exclusions continue in 2017, with CVS aggressively expanding its list of “not covered” drugs. Express Scripts currently excludes slightly fewer drugs than last year but may still add to its list.

CVS Expands Formulary Exclusions In 2017, Express Scripts’ Tally Unchanged

National formulary exclusions continue in 2017, with CVS aggressively expanding its list of “not covered” drugs. Express Scripts currently excludes slightly fewer drugs than last year but may still add to its list.

Inside The COVID-19 Bill: Breaking Down The Pharma Policy Provisions

What's in – and what fell out of – the massive US stimulus package.

Table

View full table

Topics

Related Companies

Tags:
BioPharmaceutical United States Government Payers
UsernamePublicRestriction

Register

PS057401

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By